A new dawn breaks for blood tests in neurological diseases, though future data remain important.
Pdufa dates are also set for Sarepta and UCB, and panels will discuss Leqembi and Beyfortus.
One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.
The group is taking marstacimab to the regulators, but Novo’s MAb looks like a bad omen.
An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
Fianlimab continues to look like biopharma’s leading Lag3 asset, with activity in a new melanoma setting to boot.
Annexon’s failure in geographic atrophy could clear the way for its rivals.
The FTC moves to block Amgen’s Horizon takeout, broadening its remit to curb anticompetitive moves that inflate drug prices.
Alzheimer’s has already grabbed attention but plenty of big regulatory decisions still loom for Sarepta, Crispr, Astellas and more.
With Tigit out of favour Belgium’s Iteos reckons it could have the best possible PD-(L)1 combo, but does GSK share its optimism?
In purchasing Iveric for $5.9bn the Japanese group has plumped for the cheaper geographic atrophy player.
In licensing Maze’s oral contender, the group has made another bet against gene therapies.
SRP-9001 heads for its month of regulatory probing, as vaccines from GSK and Pfizer, and Genmab and Abbvie’s bispecific, await FDA approval decisions.
Roche puts on a brave face as its anti-PD-L1 drug fails yet another TNBC study, this time in the adjuvant setting.